Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

carlumab

A human IgG1 kappa monoclonal antibody directed against human CC chemokine ligand 2 (CCL2) with potential antineoplastic activity. Carlumab binds to and inhibits CLL2, which may result in inhibition of angiogenesis and, so, tumor cell proliferation. Endothelium-derived CLL2 (monocyte chemoattractant protein; MCP1) is a member of the beta-chemokine family, can stimulate monocyte/macrophage migration and smooth muscle cell (SMC) proliferation, and plays a role in angiogenesis and tumor cell migration; CCL2 induction of angiogenesis may involve the upregulation of hypoxia-inducible factor 1 alpha (HIF-1 alpha) gene expression which, in turn, induces vascular endothelial growth factor-A (VEGF-A) gene expression.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CCL2 human monoclonal antibody CNTO 888
anti-human small-inducible cytokine A2 monoclonal antibody CNTO 888
immunoglobulin G1, anti-(human monocyte chemoattractant protein-1) (human monoclonal CNTO888 gamma 1-chain), disulfide with human monoclonal CNTO888 kappa-chain, dimer
Code name:CNTO 888
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search